Geochemical dataset of high-pressure acid migmatites from the Cabo Ortegal Complex (NW Spain)

This brief note presents geochemical data from rock samples from the Cabo Ortegal Complex (NW Spain). The samples belong to acid lithologies within the mainly basic to intermediate granulite unit that have been poorly investigated so far. For this communication, five samples of the migmatites and an amphibolitic enclave within them have been analysed. The whole-rock major and trace-element analyses were accomplished by means of Q-ICPMS. The dataset provides new and useful information relevant to the origin of the acid migmatites and can be used in addition to information from neighbouring lithologies to enhance understanding of the geological evolution of the Western Variscan Belt

Leer en comunidad: creación y desarrollo de clubes de lectura de literatura escrita por mujeres dentro y fuera de la universidad

Depto. de Lengua Española y Teoría de la LiteraturaFac. de FilologíaFALSEsubmitte

Reposicionamiento de fármacos: viejos fármacos en nuevas indicaciones terapéuticas

3 p.-3 fig.Peer reviewe

Derivatives of 2-phenyl-7,7a-dihydro-3aH-pyrano[3,4-d]oxazole-6(4H)-one

Derivatives of 2-phenyl-7,7a-dihydro-3aH-pyrano[3,4-d]oxazole-6(4H)- one of formula (I), where the meanings for the substituents are those listed in the description. These compounds are useful as inhibitors of HIF-2α and SOX-2.Peer reviewedConsejo Superior de Investigaciones Científicas (España)A1 Solicitud de patente con informe sobre el estado de la técnic

Derivados de isoindolino-1,3-diona

[EN] The invention relates to derivatives of isoindolin-1,3-dione of formula (I), where the substituents are designated in the description. These compounds can be used as HIF-2α and SOX-2 inhibitors.[ES]Derivados de isoindolino-1,3-diona de fórmula (I), donde los significados para los sustituyentes son los descritos en la descripción. Estos compuestos son útiles como inhibidores de HIF-2α y de SOX-2Peer reviewedConsejo Superior de Investigaciones Científicas (España)A1 Solicitud de patente con informe sobre el estado de la técnic

Derivatives of isoindolin-1,3-dione

Derivados de isoindolino-1,3-diona de fórmula I, donde los significados para los sustituyentes son los descritos en la descripción. Estos compuestos son útiles como inhibidores de HIF-2α y de SOX-2.Peer reviewedConsejo Superior de Investigaciones Científicas (España)A1 Solicitud de patente con informe sobre el estado de la técnic

Structure and function of prokaryotic UDP-glucose pyrophosphorylase, a drug target candidate

24 p.-9 fig.UDP-glucose is an essential metabolite for a variety of processes in the cell physiology in all organisms. In prokaryotes, it is involved in the synthesis of trehalose, an osmoprotectant, in galactose utilization via the Leloir pathway and it plays a key role in the synthesis of the components of the bacterial envelope, particularly the lipopolysaccharide and the capsule, which represent necessary virulence factors of many bacterial pathogens. UDP-glucose is synthesized in bacteria by the prokaryotic UDP-glucose pyrophosphorylase (UGP, EC 2.7.7.9), an enzyme belonging to the family of sugar:nucleotidyl transferases. Despite the ubiquitous distribution of UGP activity in all domains of life, prokaryotic UGPs are evolutionarily unrelated to their eukaryotic counterparts. Taken together, these features make of bacterial UGP an attractive target candidate for the discovery and development of new generation antibiotics. This review summarizes the current knowledge on structure and function of bacterial UGPs, underlying their potential as drug target candidates.We thank MINECO for financial support (Grant CTQ 2012-32025, AES12/PI12/01628), EU for funding through the GlycoHit, ITN-Glycopharm, FP7-HEALTH-2012-INNOVATION-1, project number: 305483 and COST actions BM1003 and CM1102, as well as Comunidad de Madrid for the MHit project. MAB acknowledges a FPI fellowship from MINECO.Peer reviewe

FM19G11 reverses endothelial dysfunction in rat and human arteries through stimulation of the PI3K/Akt/eNOS pathway, independently of mTOR/HIF-1α activation

53 p.-7 fig.BACKGROUND AND PURPOSE FM19G11 up-regulates mammalian target of rapamycin (mTOR)/hypoxia inducible factor-1α (HIF-1α) and PI3K/Akt pathways, which are involved in endothelial function. We evaluated the effects of FM19G11 on defective endothelial vasodilatation in arteries from rats and humans and investigated the mechanisms involved.EXPERIMENTAL APPROACH Effects of chronic in vivo administration of FM19G11 on aortic endothelial vasodilatation were evaluated together with ex vivo treatment in aortic and mesenteric arteries from control and insulin-resistant rats (IRR). Its effects on vasodilator responses of penile arteries (HPRAs) and corpus cavernosum (HCC) from men with vasculogenic erectile dysfunction (ED) (model of human endothelial dysfunction) were also evaluated. Vascular expression of phosphorylated-endothelial NOS (p-eNOS), phosphorylated-Akt (p-Akt) and HIF-1α was determined by immunodetection and cGMP by ELISA.KEY RESULTS Chronic administration of FM19G11 reversed the impaired endothelial vasodilatation in IRR. Ex vivo treatment with FM19G11 also significantly improved endothelium-dependent vasodilatation in aorta and mesenteric arteries from IRR. These effects were accompanied by the restoration of p-eNOS and cGMP levels in IRR aorta and were prevented by either NOS or PI3K inhibition. p-Akt and p-eNOS contents were increased by FM19G11 in aortic endothelium of IRR. FM19G11-induced restoration of endothelial vasodilatation was unaffected by mTOR/HIF-1α inhibitors. FM19G11 also restored endothelial vasodilatation in HPRA and HCC from ED patients.CONCLUSIONS AND IMPLICATIONS Stimulation of the PI3K/Akt/eNOS pathway by FM19G11 alleviates impaired NO-mediated endothelial vasodilatation in rat and human arteries independently of mTOR/HIF-1α activation. This pharmacological strategy could be beneficial for managing pathological conditions associated with endothelial dysfunction, such as ED.This research work was supported by grants from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III, PI10/02781, PI11/01068, PI12/01628, S2010/BMD-2353, RETICEF RD12/0043), Spanish Government, and the Fundación Mutua Madrileña (AP103152012).Peer reviewe